Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensingIntranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challengePreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineA throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoVInfluenza A: a threatening virus with two faces.New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors.1918 influenza pandemic caused by highly conserved viruses with two receptor-binding variants.Preparing for the first influenza pandemic of the 21st century.Oseltamivir in the management of influenza.Functional and antigenic analyses of the 1918 influenza virus haemagglutinin using a recombinant vaccinia virus expression system.The survival of influenza A(H1N1)pdm09 virus on 4 household surfaces.Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection.The threat of avian influenza H5N1: 'do we have the tools for the job'?Animal models in influenza vaccine testing.Meeting report: risk assessment of tamiflu use under pandemic conditions.Antivirals for the treatment and prevention of epidemic and pandemic influenzaA plant-produced influenza subunit vaccine protects ferrets against virus challengePharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.Potential role of human challenge studies for investigation of influenza transmission.Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.Clinical, scientific and ethnographic studies of influenza in quarantine.Viral load drives disease in humans experimentally infected with respiratory syncytial virusCorrelation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccinationA new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.Human genetics and responses to influenza vaccination: clinical implications.Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.The Determinants of Reported Personal and Household Hygiene Behaviour: A Multi-Country Study.An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with InfectionA Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine.Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study.DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial.In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection.A view from the virology research laboratoryNon-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine.Modification of pH Conferring Virucidal Activity on Dental Alginates.Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.Factors influencing inappropriate antibiotic prescription in Europe.The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults: measurement of cardiac troponins I and T in 152 patients with acute influenza infection.
P50
Q27003874-461577C2-4853-4F88-BA93-F3B12F5B99D4Q27345256-DE94651C-E6AD-4818-8724-59A9C28C7D22Q27347652-2F28A634-5B75-4C2F-B901-9B374F07D076Q28250266-438A8A68-DE2B-4ED4-8944-CA7D0D7626F6Q30330075-4C8E6D2E-125D-41D0-BD8C-45E039AAEDB1Q30332341-6EFB79F1-45F5-432C-B478-A1B0F2D78182Q30336398-F56DA1B0-0500-4A1B-B7B2-D02A27F08B1AQ30350372-1085CD69-E242-4044-AECF-A6604424D9DCQ30351736-8345CCFE-1ED3-41CC-AD03-AE19E5D671EBQ30356237-71020E84-18FC-4CD9-B2D1-52454523F39CQ30360747-B875183C-AB44-4645-ADC5-5DCC08EBF0EBQ30361760-517097E7-669D-43F8-9ABD-B9C7B36A121AQ30362060-E19ABF4A-97FC-4225-B2B5-CCD791252C43Q30371058-FE306E41-B01B-40EE-860A-5686C1B0DE4CQ30373734-8AD7C8BC-3F2B-4362-97DE-0CAABBBB037CQ30377241-3B5385E6-8D88-4CBB-9FAB-569B45833089Q30377250-2FCA4626-DFE2-485D-B9D5-7156E1CE9DC8Q30397016-B54E4D07-B5E3-463C-9E19-7B5122318122Q30405341-C0877CBD-A872-40A4-9823-FB6EED5DB587Q30412301-E95904E8-8B77-4182-BEBA-123253F8E8D8Q30421545-03AD982F-6AC8-40D8-96B0-B2CAB483C9F0Q34402459-ECD32263-B943-4894-8380-B7830699399CQ34949435-B0F0505B-4BB9-4418-8616-56A453EB5972Q35612523-75E4DD83-510E-49C8-8E33-8EE6F621BB77Q35907542-08DB6445-A9C2-4B5E-8D0E-B298BD4F9B39Q36014866-2DA29B61-72C3-4740-A0CA-7DE572B48EAAQ36058647-31D10055-E50F-461C-97B8-1F256F198D48Q36107820-BA4D15DF-99CE-41D9-B649-A800B65C03A6Q36231510-14B4692A-68A7-4AD3-AD4E-B46A458A63F1Q39132587-67056594-75F1-4B17-8C05-B67F4CFB8967Q39588353-CA77A785-BAEA-4A9F-8F3C-2ABE8BF0D783Q39680798-A1090DED-F71E-4BF5-8337-A730B3236114Q40392276-35DFAFAA-E900-4454-8741-0A4F86882639Q40438433-3474EF97-78F5-4875-AFF8-FA8829C6CB92Q40611267-0EC279CE-A093-445C-B179-07A1D237AA5AQ40640922-21A50584-51DC-4BF6-93B7-8162D0147DC0Q40992726-8FE87416-FE94-47EA-A9CA-678921AF18B9Q42243814-7850937A-47DD-4213-B3E5-D4EAD9F3205AQ43972907-9C22009E-4113-48D8-9F6A-2270B02C3FEDQ44290451-21543D79-CBE4-4E78-9E54-35BA43913DAF
P50
description
British virologist
@en
virólogo británico
@es
virólogu británicu
@ast
عالم فيروسات من المملكة المتحدة
@ar
name
John Oxford
@ast
John Oxford
@ca
John Oxford
@cs
John Oxford
@de
John Oxford
@en
John Oxford
@es
John Oxford
@fr
John Oxford
@hu
John Oxford
@sl
ジョン・オクスフォード
@ja
type
label
John Oxford
@ast
John Oxford
@ca
John Oxford
@cs
John Oxford
@de
John Oxford
@en
John Oxford
@es
John Oxford
@fr
John Oxford
@hu
John Oxford
@sl
ジョン・オクスフォード
@ja
altLabel
J Oxford
@en
J S Oxford
@en
J. Oxford
@en
J. S. Oxford
@en
John S Oxford
@en
John S. Oxford
@en
John Sydney Oxford
@en
Oxford J
@en
Oxford J. S.
@en
Oxford J.
@en
prefLabel
John Oxford
@ast
John Oxford
@ca
John Oxford
@cs
John Oxford
@de
John Oxford
@en
John Oxford
@es
John Oxford
@fr
John Oxford
@hu
John Oxford
@sl
ジョン・オクスフォード
@ja